This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / China NMPA Grants Priority Review to...
Regulatory Regulatory approval

China NMPA Grants Priority Review to Leqembi SC-AI

Analysis based on 7 articles · First reported Feb 09, 2026 · Last updated Feb 09, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The priority review designation for Leqembi's subcutaneous formulation in China is expected to accelerate its market entry, positively impacting BioArctic and Eisai's stock prices due to increased sales potential in a large market. This development also signals a streamlined Alzheimer's disease treatment pathway, potentially reducing healthcare costs and improving patient access.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Eisai, in partnership with BioArctic, announced that the Biologics License Application (BLA) for the subcutaneous autoinjector formulation of Leqembi (lecanemab) for early Alzheimer's disease has been granted Priority Review by the China===National Medical Products Administration (NMPA) in China. This designation is expected to shorten the assessment period for the drug, potentially allowing for a quicker launch. If approved, the subcutaneous formulation would offer a convenient once-weekly at-home treatment option, reducing the need for bi-weekly intravenous administration in hospitals and streamlining healthcare resources. Leqembi was launched in China in June 2024 and was recently included in China's 'Commercial Insurance Innovative Drug List,' further enhancing patient access. This development is a significant step for BioArctic and Eisai in expanding the global reach and accessibility of Leqembi, which is already approved in 53 countries.

Key Actions
95 China===National Medical Products Administration designated for Priority Review Eisai
90 Eisai submitted Biologics License Application for subcutaneous formulation of Leqembi China===National Medical Products Administration
80 China included Leqembi in Commercial Insurance Innovative Drug List Eisai
70 Eisai launched Leqembi in China China
60 United States===Food and Drug Administration granted Priority Review for subcutaneous starting dose of Leqembi Iqlik Eisai
Entities Involved
stock
Eisai
Eisai, BioArctic's partner, is responsible for the clinical development and commercialization of Leqembi globally. The priority review in China and the potential approval of the subcutaneous formulation will enhance Eisai's market position and revenue potential for Leqembi.
Importance 95 Sentiment 70
stock
BioArctic
BioArctic, as the inventor of Leqembi, stands to benefit significantly from the expanded market access and potential for increased sales in China. The priority review designation for the subcutaneous formulation of Leqembi in China is a positive development for BioArctic.
Importance 90 Sentiment 70
cnt
China
China represents a significant market for Alzheimer's disease treatments, with an estimated 17 million patients in 2024. The potential approval of Leqembi's subcutaneous formulation and its inclusion in the 'Commercial Insurance Innovative Drug List' will improve access to innovative medicines for its aging population.
Importance 85 Sentiment 0
govactor
China===National Medical Products Administration
The China===National Medical Products Administration (NMPA) of China designated the Biologics License Application for Leqembi's subcutaneous formulation for Priority Review, which will accelerate its potential approval and market entry in China.
Importance 80 Sentiment 0
per
Lars Lannfelt
Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease was foundational to the development of Leqembi by BioArctic.
Importance 30 Sentiment 0
stock
Biogen
Biogen is involved in a joint development and commercialization agreement for lecanemab with Eisai, and also participates in the AHEAD 3-45 clinical study.
Importance 20 Sentiment 0
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration (FDA) granted Priority Review for Eisai's supplemental Biologics License Application for a subcutaneous starting dose with Leqembi Iqlik in January 2026, indicating ongoing regulatory progress in the US market.
Importance 20 Sentiment 0
+ 2 more entities View on Dashboard
Relationships
BioArctic related ↔ Eisai
Eisai related ↔ Biogen
China related ↔ China===National Medical Products Administration
Lars Lannfelt related ↔ BioArctic
BioArctic related ↔ China===National Medical Products Administration
BioArctic related ↔ China
Eisai related ↔ China===National Medical Products Administration
Eisai related ↔ China
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.